BiotechBlog is syndicated by BlogBurst, which means that posts are syndicated to outlets such as Reuters, Biospace, San Francisco Gate, and dozens of other media outlets.

Post your content on BiotechBlog and have it syndicated across the web. To create a dialogue for important issues in biotechnology, BiotechBlog is adopting an open architecture. All user accounts have the ability to post articles (which are subject to review prior to posting). Give it a shot. Go head and create an account, get on your soapbox, and post some guest content. If you’d prefer not to create an account, drop me a line at the contact form, and I’ll post your submission directly.

Guidelines for submissions are:

• BiotechBlog focuses on commercial, legal, political, and scientific trends in biotechnology. Your post should fit this framework.
• Posts should be action-oriented (case studies, best practices, guidelines, etc.) or otherwise insightful (perspectives, backgrounders, op-ed’s, etc.) , and not simply rehash press releases or promote commercial services.
• Please refrain from self-references in the body of posts. You are free to post a byline with a link to your site at the end of articles.
• You can view other guest content here.

Questions? Use the contact form.

1. [...] Guest content from John Avellanet, managing director and principal of Cerulean Associates: [...]

   Posted by Biotech Blog » Generic Biologics: How to Compete | February 26, 2008, 8:52 am

2. [...] Guest content from John Avellanet, managing director and principal of Cerulean Associates: [...]

   Posted by smaranya.com » Generic Biologics: How to Compete | March 1, 2008, 1:25 am

3. [...] guest editorial from Emil Ciurczak, Contributing Editor, [...]

   Posted by Biotech Blog | `Til Death Do Us Part, But First, the Pre-Nup: Why CAPA Needs to Evolve | May 30, 2008, 1:55 am